ArticleNorthern clinics of Istanbul2025
Tenascin-C levels in polycystic ovary syndrome and polycystic ovarian morphology.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIt is considered that the underlying reason for metabolic anomalies and ovarian dysfunction in polycystic ovary syndrome (PCOS) is low-grade chronic inflammation. Therefore, we aimed to investigate Tenascin-C (TN-C) levels in PCOS. This is the first study to document the impact of inflammation with TN-C in this specific population.
methodsA total of 90 participants, consisting of 30 PCOS patients, 30 polycystic ovarian morphology (PCOM) patients, and 30 matched healthy controls between September 2018 and April 2019 enrolled. All participants were randomized by age and body mass index. Demographic, clinical characteristics, ultrasonographic features, lipid profile, hormonal and metabolic parameters were collected.
resultsWhen comparing serum TN-C levels between PCOS, PCOM and control subjects, a statistically significant difference was observed only between subjects with PCOS and control subjects (p=0.009). ROC analysis demonstrated that PCOS could be predicted with 89.7% sensitivity and 45.5% specificity when TN-C levels are cut off at 1.87 ng/ml.
conclusionThis study indicated that TN-C level was higher in the PCOS group compared to PCOM and control groups, while it was similar between the PCOM and the control groups. It may be suggested that TN-C levels may contribute to the differentiation between PCOS and PCOM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.